A Delaware federal judge ruled that Novartis AG cannot block MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto before the patent expires in late 2026. The judge found that MSN's generic version does not infringe on a key Novartis patent, rejecting Novartis' request for a preliminary injunction to stop the generic launch. Following this ruling, MSN Laboratories Ltd. is permitted to sell its generic Entresto upon FDA approval. However, Novartis Pharmaceuticals Corp. later convinced the Federal Circuit to impose a temporary block on MSN's generic launch while the parties continue to dispute the matter, indicating ongoing legal contention over the patent and market entry timing.